IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re United State	es Patent Application of:	Confirmation No.	8073
Applicant:	Richard A. Soltero	Atty. Docket No.	025333-003
Application No.:	10/590,282	Examiner:	-
Date Filed:	August 22, 2006	Group Art Unit:	1614
Title:	METHOD FOR ADMINISTERING MEDICAMENTS TO SUBJECTS WITH SWALLOWING DIFFICULTIES AND DISORDERS	Customer No: 24.	
SUE	BMISSION OF INFORMAT	TON DISCLOSURE STA	ATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449.

	.,	
⊠ 1.	OR be	nformation Disclosure Statement is being filed within three months of the U.S. filing date fore the mailing date of a first Office Action on the merits issued for the recently filed RCE tion. No certification or fee is required.
☐ 2.	This Information Disclosure Statement is being filed more than three months after the U date AND after the mailing date of the first Office Action on the merits, but before the date of a Final Rejection or Notice of Allowance.	
	☐ a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
	□ b.	I hereby certify that no item of information in this Information Disclosure Statement was

Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this

	∐ c.	Fee in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. \$1.17(p) is being submitted via Electronic transfer. Please credit or debit Deposit Account No. 13- 4365 as needed to ensure consideration of the disclosed information.
□ 3.	date ar the Iss conside §1.17(i 13-436	formation Disclosure Statement is being filed more than three months after the U.S. filing da after the mailing date of a Final Rejection or Notice of Allowance, but before payment of use Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be reed. Fee in the amount of \$180.00 in payment of the petition fee under 37 C.F.R.)(1) is being submitted via Electronic transfer. Please credit or debit Deposit Account No. 5 as needed to ensure consideration of the disclosed information. Two duplicate copies of per are attached.
	☐ a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
	□ b.	I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,

Marianne Fuierer Registration No. 39,983 Attorney for Applicants